title: Macrophage regulation of tumor responses to anticancer therapies.
abstract: Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either enhance or antagonize the antitumor efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies, and immunotherapeutic agents--depending on the type of treatment and tumor model. TAMs also drive reparative mechanisms in tumors after radiotherapy or treatment with vascular-targeting agents. Here, we discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target TAMs to increase the efficacy of such therapies.
authors.affiliation: The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), CH-1015 Lausanne, Switzerland. michele.depalma@epfl.ch
authors.forename: Michele
authors.initials: M
authors.lastname: De Palma
authors.forename: Claire E
authors.initials: CE
authors.lastname: Lewis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents